Fasoracetam (NS-105) Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Fasoracetam (NS-105) dosing: protocols, safety, and where to buy.
Half-Life
Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039).
Administration Routes
Dosage Calculator
Calculate exact dosing for Fasoracetam (NS-105).
Dosing data for Fasoracetam (NS-105) is being researched. Check the compound page for the latest information.
Side Effects & Safety
Contraindications
No formal contraindications have been established. Fasoracetam is excreted mostly unchanged through the kidneys (PMID: 29339723), so reduced renal function would be expected to raise exposure. In rats, radiolabeled NS-105 transferred into the fetus and into milk after a single oral dose (PMID: 10635441), which is a mechanism-based reason to avoid use in pregnancy and lactation. Repeated administration increased GABA-B receptor numbers in rat cerebral cortex (PMID: 9424016), so the pharmacology of repeated exposure is not the same as that of a single dose.
Frequently Asked Questions
What is the recommended Fasoracetam (NS-105) dosage?
Dosage for Fasoracetam (NS-105) varies by protocol. Consult a qualified healthcare provider.
How often should I take Fasoracetam (NS-105)?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Fasoracetam (NS-105) need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Fasoracetam (NS-105) side effects?
The only published human safety dataset comes from the 30-adolescent open-label study, where the most common adverse events were headache in 63.3 percent, fatigue in 36.7 percent and abdominal pain in 26.7 percent, generally mild, and where the frequency of adverse events during the single-blind placebo week did not differ from any active drug week (PMID: 29339723). The larger placebo-controlled ADHD trials completed in 2018 (NCT03265119; NCT03609619) and the 2023 crossover trial in 22q11 deletion syndrome (NCT05290493) posted results on ClinicalTrials.gov, and the ADHD sponsor described the drug as safe and well tolerated. No long-term human safety data have been published.
Where can I buy Fasoracetam (NS-105)?
Compare 1 listings from 1 vendor on our price comparison page, starting from $49.99.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.